The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 2, 2014, Pages 197-205

  Hethershaw, E L ^a   Cilia La Corte, A L ^a   Duval, C ^a   Ali, M ^a   Grant, P J ^a   Ariens R A S ^a   Philippou, H ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Blood coagulation; Electron microscopy; Factor XIII; Fibrin; Fibrinolysis

Indexed keywords

ALPHA 2 ANTIPLASMIN; FIBRIN;

ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; CROSS LINKING; DRUG ACTIVITY; FIBER; FIBRIN CLOT; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

BLOOD COAGULATION; ELECTRON MICROSCOPY; FACTOR XIII; FIBRIN; FIBRINOLYSIS;

CHROMATOGRAPHY, GEL; FACTOR XIII; FIBRIN; FIBRINOLYSIS; HUMANS; MICROSCOPY, CONFOCAL;

EID: 84893567786     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12455     Document Type: Article

References (35)

1. Doolittle RF. Fibrinogen and fibrin. In: Bloom A, Forbes C, Thomas D, Tuddenham E, eds. Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone, 1994: 491-513.
2. Schroeder V, Kohler HP. New developments in the area of factor XIII. J Thromb Haemost 2013; 11: 234-44.
3. Muszbek L, Bereczky Z, Bagoly Z, Komaromi I, Katona E. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011; 91: 931-72.
4. Takagi T, Doolittle RF. Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin. Biochemistry 1974; 13: 750-6.
5. Lorand L, Gray AJ, Brown K, Credo RB, Curtis CG, Domanik RA, Stenberg P. Dissociation of the subunit structure of fibrin stabilizing factor during activation of the zymogen. Biochem Biophys Res Commun 1974; 56: 914-22.
6. Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936: 291-311.
7. Sakata Y, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-7.
8. Undas A, Ariens RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31: e88-99.
9. Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through alpha(2)-antiplasmin cross-linking. Blood 2011; 117: 6371-4.
10. Smith EL, Cardinali B, Ping L, Ariens RA, Philippou H. Elimination of coagulation factor XIII from fibrinogen preparations. J Thromb Haemost 2013; 11: 993-5.
11. Ajjan R, Lim BC, Standeven KF, Harrand R, Dolling S, Phoenix F, Greaves R, Abou-Saleh RH, Connell S, Smith DA, Weisel JW, Grant PJ, Ariens RA. Common variation in the C-terminal region of the fibrinogen beta-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood 2008; 111: 643-50.
12. Philippou H, Rance J, Myles T, Hall SW, Ariens RA, Grant PJ, Leung L, Lane DA. Roles of low specificity and cofactor interaction sites on thrombin during factor XIII activation. Competition for cofactor sites on thrombin determines its fate. J Biol Chem 2003; 278: 32020-6.
13. Standeven KF, Carter AM, Grant PJ, Weisel JW, Chernysh I, Masova L, Lord ST, Ariens RA. Functional analysis of fibrin {gamma}-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. Blood 2007; 110: 902-7.
14. Collet JP, Moen JL, Veklich YI, Gorkun OV, Lord ST, Montalescot G, Weisel JW. The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis. Blood 2005; 106: 3824-30.
15. Ariens RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-95.
16. Woodhead JL, Nagaswami C, Matsuda M, Arocha-Pinango CL, Weisel JW. The ultrastructure of fibrinogen Caracas II molecules, fibers, and clots. J Biol Chem 1996; 271: 4946-53.
17. Mutch NJ, Moir E, Robbie LA, Berry SH, Bennett B, Booth NA. Localization and identification of thrombin and plasminogen activator activities in model human thrombi by in situ zymography. Thromb Haemost 2002; 88: 996-1002.
18. Dunn EJ, Philippou H, Ariens RA, Grant PJ. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49: 1071-80.
19. Weisel JW, Veklich Y, Collet JP, Francis CW. Structural studies of fibrinolysis by electron and light microscopy. Thromb Haemost 1999; 82: 277-82.
20. Scott DJ, Prasad P, Philippou H, Rashid ST, Sohrabi S, Whalley D, Kordowicz A, Tang Q, West RM, Johnson A, Woods J, Ajjan RA, Ariens RA. Clot architecture is altered in abdominal aortic aneurysms and correlates with aneurysm size. Arterioscler Thromb Vasc Biol 2011; 31: 3004-10.
21. Undas A, Nowakowski T, Ciesla-Dul M, Sadowski J. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans. Atherosclerosis 2011; 215: 481-6.
22. Rooth E, Wallen NH, Blomback M, He S. Decreased fibrin network permeability and impaired fibrinolysis in the acute and convalescent phase of ischemic stroke. Thromb Res 2011; 127: 51-6.
23. Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, Ankri A, Blanchet B, Dumaine R, Gianetti J, Payot L, Weisel JW, Montalescot G. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-73.
24. Chernysh IN, Weisel JW. Dynamic imaging of fibrin network formation correlated with other measures of polymerization. Blood 2008; 111: 4854-61.
25. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-31.
26. Ryan EA, Mockros LF, Weisel JW, Lorand L. Structural origins of fibrin clot rheology. Biophys J 1999; 77: 2813-26.
27. Kimura S, Aoki N. Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor. J Biol Chem 1986; 261: 15591-5.
28. Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, Weisel JW. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-61.
29. Sakharov DV, Rijken DC. The effect of flow on lysis of plasma clots in a plasma environment. Thromb Haemost 2000; 83: 469-74.
30. Mutch NJ, Engel R, de Uitte WS, Philippou H, Ariens RA. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood 2010; 115: 3980-8.
31. Longstaff C, Thelwell C, Williams SC, Silva MM, Szabo L, Kolev K. The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies. Blood 2011; 117: 661-8.
32. Muszbek L, Bagoly Z, Bereczky Z, Katona E. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc Hematol Agents Med Chem 2008; 6: 190-205.
33. Carlisle CR, Sparks EA, der Loughian C, Guthold M. Strength and failure of fibrin fiber branchpoints. J Thromb Haemost 2010; 8: 1135-8.
34. Tsurupa G, Hantgan RR, Burton RA, Pechik I, Tjandra N, Medved L. Structure, stability, and interaction of the fibrin(ogen) alphaC-domains. Biochemistry 2009; 48: 12191-201.
35. Weisel JW, Nagaswami C, Makowski L. Twisting of fibrin fibers limits their radial growth. Proc Natl Acad Sci U S A 1987; 84: 8991-5.